Article Text
PDF
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Is once-daily atomoxetine more effective than placebo at reducing attention deficit hyperactivity disorder (ADHD) symptoms displayed at school?
METHODS
Design:
Multicentre randomised controlled trial.
Allocation:
Concealed.
Blinding:
Double blind.
Follow up period:
Seven weeks.
Setting:
Eight sites in the USA, two in Canada, and one in Puerto Rico.
Patients:
153 children aged 8–12 years with ADHD (DSM-IV); with symptom severity on the investigator administered ADHD Rating Scale-IV-Teacher Version (ADHDRS-IV-Teacher:Inv) at least 1.0 standard deviation (SD) above age and gender norms, and at least 1.5 SD above norms on …
Footnotes
For correspondence: Dr A J Allen, Lilly Corporate Center, Indianapolis, IN 46285, USA; allenaj{at}lilly.com
Sources of funding: Eli Lilly and Company.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.